Bristol-Myers Squibb (BMY)

Bristol Myers Squibb (NYSE: BMY), a global leader in oncology, today announced the evolution of Standing in the Gaap, a long-running program designed to help address persistent gaps in care for people living with multiple myeloma (MM) in medically underserved communities. Building on a decade of sustained commitment, BMS is reinforcing its focus on equitable access to multiple myeloma education, resources, and community-driven solutions by expanding the program to reach more patients and care partners.

Bristol Myers Squibb (NYSE: BMY) today announced positive data from the Phase 3 SCOUT-HCM trial of Camzyos (mavacamten), the first study of a cardiac myosin inhibitor (CMI) in adolescents (ages 12 years to <18 years) with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The SCOUT-HCM trial met its primary endpoint, demonstrating a clinically meaningful and statistically significant reduction from baseline in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 with Camzyos versus placebo, with a significant least-squares (LS) mean difference (95% CI) at Week 28 of −48.0 (−67.7, −28.3) mm Hg; P < 0.0001.

Bristol Myers Squibb (NYSE: BMY) today announced data from a Phase 4 clinical trial evaluating the symptom stability, safety and tolerability of Cobenfy (xanomeline and trospium chloride) when switching adult outpatients with schizophrenia from an oral atypical antipsychotic to Cobenfy monotherapy. Through 8 weeks, patients remained stable with mean Positive and Negative Syndrome Scale (PANSS) total scores remaining below baseline, and no new safety signals were observed, regardless of cross-titration duration. These findings provide important evidence to help inform treatment switch strategies in clinical practice. Data were presented at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS) taking place March 25-29 in Florence, Italy.

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of new clinical trial and real-world data for Camzyos (mavacamten) at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo, taking place March 28–30, 2026, in New Orleans, Louisiana. Presentations at ACC will build upon the most comprehensive and mature evidence base in symptomatic obstructive hypertrophic cardiomyopathy (oHCM), further establishing Camzyos as a paradigm-shifting therapy across a range of patient populations. New data include multiple real-world data analyses demonstrating the consistent effectiveness and safety profile of Camzyos in adults, as well as full results from SCOUT-HCM, the first Phase 3 clinical trial evaluating a cardiac myosin inhibitor (CMI) as a potential treatment for adolescents with oHCM.

Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo® (nivolumab) has received approval for two new classical Hodgkin Lymphoma (cHL) indications in the U.S. and the European Union (EU). The U.S. Food and Drug Administration (FDA) granted approval of Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD) for the treatment of adult and pediatric patients 12 years and older with previously untreated, Stage III or IV cHL.1 In the EU, the European Commission (EC) approved Opdivo in combination with brentuximab vedotin for the treatment of children 5 years of age and older, adolescents, and adults up to 30 years of age with relapsed or refractory cHL after one prior line of therapy.2

Bristol Myers Squibb (NYSE: BMY) will announce results for the first quarter of 2026 on Thursday, April 30, 2026. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET.

Bristol Myers Squibb (NYSE: BMY) today announced positive interim Phase 3 results from the SUCCESSOR-2 study (NCT05552976). In the trial, oral mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus carfilzomib and dexamethasone alone (Kd) in patients with relapsed or refractory multiple myeloma (RRMM). Safety findings were consistent with the known profile of mezigdomide and the combination regimen. Patients will continue to be followed for survival and safety.

Bristol Myers Squibb (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Sotyktu® (deucravacitinib) for the treatment of adults with active psoriatic arthritis (PsA).1 Sotyktu, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, is the first TYK2 inhibitor to be approved for PsA.

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the company.

SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced that SystImmune’s parent company, Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin), reported positive topline results from a pre-specified interim analysis of a Phase III study (BL-B01D1-307) evaluating izalontamab brengitecan (iza-bren), an EGFR×HER3 bispecific antibody-drug conjugate (ADC), in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose disease progressed following prior taxane therapy.

EQNX::TICKER_START (NASDAQ:HELP),(CBOE:HELP),(NYSE:TAK),(NASDAQ:CMPS),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026.

Bristol Myers Squibb (NYSE: BMY) today announced positive top-line results from the ongoing, ex-US, Phase 2 registrational study (NCT05664737) evaluating Reblozyl® (luspatercept-aamt) versus placebo for anemia in adults with Alpha (α)-Thalassemia.

Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for iberdomide combined with standard treatment (daratumumab + dexamethasone - IberDd) in patients with relapsed or refractory multiple myeloma (RRMM). Iberdomide is part of an investigational, new class of medicines called cereblon E3 ligase modulator (CELMoD) agents. The FDA has granted a Prescription Drug User Fee Act (PDUFA) date of August 17, 2026 for this indication.

Bristol Myers Squibb (NYSE: BMY) today reported fourth quarter and full-year 2025 financial results.

Bristol Myers Squibb (NYSE: BMY) today announced they have teamed up with renowned goalkeeper and sports commentator Kasey Keller, who is publicly sharing his personal experience with non-Hodgkin lymphoma (NHL) for the first time. His story details a long and challenging treatment journey that ultimately led him to Breyanzi® (lisocabtagene maraleucel; liso-cel), a personalized CD19-directed CAR T cell therapy made from a patient’s own T cells and administered as a one-time infusion*. Through this collaboration, Kasey aims to empower and inform others navigating their own blood cancer diagnosis, drawing from his unique experience, because with Breyanzi, Cure is the Goal**.

Bristol Myers Squibb (NYSE: BMY) announced today the launch of "Change the Target. Change What’s Possible." an educational campaign developed in partnership with Johnson & Johnson for clinicians who manage cardiovascular and thromboembolic conditions. The program spotlights the unmet need in cardiovascular care for patients who, despite currently available therapies, remain at high risk of thromboembolic events, underscoring the need for new innovations to help address one of the leading causes of death and disability in the U.S. The unmet need is significant - 40% of patients with atrial fibrillation are untreated or undertreated, and roughly 25% of strokes are recurrent, many of which are considered preventable - with potential bleeding risks contributing to gaps in protection.

Bristol Myers Squibb (NYSE: BMY, “BMS”), a global leader in oncology, today announced an agreement with Microsoft, a market leader in AI-powered radiology and clinical workflow technologies, aiming to accelerate early detection of lung cancer.

Bristol Myers Squibb (NYSE: BMY) today announced positive topline results from SCOUT-HCM, a Phase 3 trial evaluating Camzyos (mavacamten) in the first study of a cardiac myosin inhibitor (CMI) in adolescents (ages 12 years to <18 years) with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The trial met its primary endpoint, demonstrating a statistically significant reduction from baseline in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 versus placebo, indicating Camzyos was effective in improving LVOT obstruction. Statistical significance was also met for multiple secondary endpoints, including those for clinically meaningful aspects of the disease. Safety results in the trial were consistent with the established safety profile of Camzyos in adults, and no new safety signals were reported in this new, younger population. The study continues with active treatment and long-term extension periods.

Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at J.P. Morgan’s 44th Annual Healthcare Conference on Monday, January 12, 2026.

Bristol Myers Squibb (NYSE: BMY, “BMS”) today announced an agreement with the U.S. government to provide Eliquis® (apixaban), an oral anticoagulant relied upon by millions of Americans daily, for free to the Medicaid program and to donate more than seven tons of Eliquis active pharmaceutical ingredient (API) to ensure American supply chain resilience. The agreement is aligned with BMS’s ongoing commitment to advancing cardiovascular health, improving patient outcomes and collaborating with policymakers on solutions that lower costs for American patients and the healthcare system without jeopardizing future innovation.

Bristol Myers Squibb (NYSE: BMY) will announce results for the fourth quarter of 2025 on Thursday, February 5, 2026. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET.

Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to the supplemental Biologics License Application (sBLA) for Opdivo® (nivolumab) in combination with doxorubicin, vinblastine and dacarbazine (AVD) for adult and pediatric (12 years and older) patients with previously untreated Stage III or IV classical Hodgkin Lymphoma (cHL). The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 8, 2026.

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the company. The dividend is payable on February 2, 2026, to stockholders of record at the close of business on January 2, 2026.

Bristol Myers Squibb (NYSE: BMY) reinforces its hematology leadership through new research across multiple therapies for patients with lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting.